Home › Topics › Opioid Crisis

Opioid Crisis

GMJ News knowledge hub · last reviewed August 2026 · Georgian Medical Journal

SummaryStatisticsGlossaryGMJ newsFAQDocumentsOrganizationsResearch

The opioid crisis — centred in North America but increasingly global — caused over 80,000 overdose deaths in the US in 2024 (CDC), with over 70% involving illicitly manufactured fentanyl (50-100× more potent than morphine) and its analogues (carfentanil — 10,000× morphine); representing the deadliest drug crisis in US history and an accelerating public health emergency defined by four successive epidemic waves from prescription opioids (1990s) to heroin (2010s) to synthetic fentanyl (2013-present) to polysubstance combinations (fentanyl + methamphetamine/cocaine) (WHO). Naloxone (an opioid receptor antagonist reversing overdose in 2-3 minutes) is on the WHO Essential Medicines List — its community distribution and layperson administration is the single most evidence-based harm reduction intervention, alongside medications for opioid use disorder (MOUD): methadone, buprenorphine and extended-release naltrexone.

Key messages

80K+ US overdose deaths/year — 70%+ involve fentanyl
Over 80,000 people die from drug overdoses in the US each year (CDC 2024), with over 70% of these deaths involving illicitly manufactured fentanyl (IMF) or its analogues — making synthetic opioids the deadliest drug crisis in US history and an accelerating global concern (WHO).
Naloxone reverses overdose in 2-3 minutes — life-saving
Naloxone (Narcan) — an opioid receptor antagonist — rapidly reverses opioid overdose when administered as a nasal spray, IM injection or auto-injector, restoring consciousness and breathing within 2-3 minutes. WHO EML listing; community distribution to people who use drugs and their families saves lives.
Methadone and buprenorphine — evidence-based treatments
Medications for opioid use disorder (MOUD): methadone (full opioid agonist — supervised dispensing) and buprenorphine/naloxone (Suboxone — partial agonist, office-based prescribing) reduce illicit opioid use, overdose mortality and injection-related infections by 50-70%. Extended-release naltrexone (monthly injection) is an alternative for those fully detoxified.
Four epidemic waves — from OxyContin to fentanyl
The US opioid epidemic has had four overlapping waves: (1) 1990s-2010s: prescription opioids (OxyContin/oxycodone); (2) 2010s: heroin (as prescription opioids became harder to obtain); (3) 2013-present: synthetic fentanyl (50-100× potency of morphine); (4) 2019-present: fentanyl + stimulants (methamphetamine, cocaine) — the current phase, hardest to treat.
Harm reduction saves lives — needle exchange, drug checking
Needle and syringe programmes (NSPs) reduce HIV and HCV transmission. Fentanyl test strips detect fentanyl contamination in other drugs (increasingly available in the US and Europe). Drug consumption facilities (DCRs) — supervised injection sites — have not had a single overdose death in decades of operation globally.
The global dimension — not just a US problem
Prescription opioid overdose crises are emerging in Australia, Canada and the UK. The WHO global opioid use disorder burden is 27 million people. Russia has approximately 2 million people with opioid use disorder (krokodil — desomorphine — historically). UNODC estimates 62 million people use opioids globally (licit + illicit).

Key statistics

80K+
drug overdose deaths/year in US — 70%+ synthetic opioids (CDC 2024)
CDC 2024
27M
people with opioid use disorder globally (WHO/UNODC)
WHO/UNODC
50-100×
fentanyl potency vs morphine; carfentanil 10,000×
CDC/DEA
50-70%
overdose mortality reduction with MOUD (methadone/buprenorphine)
Cochrane/WHO
2-3min
naloxone reversal time for opioid overdose
WHO/EML
0
overdose deaths at supervised drug consumption facilities globally
WHO/Harm reduction

US opioid overdose deaths by drug type — four epidemic waves 1999-2024 (CDC)

Source: CDC. Wave 4: fentanyl + stimulants now driving deaths. Each wave built on the previous.

Glossary of key terms

Illicitly manufactured fentanyl (IMF)
CDC/DEASynthetic fentanyl and analogues (acetylfentanyl, carfentanil, nitazenes) produced in clandestine laboratories — predominantly in Mexico using precursor chemicals from China — and distributed mixed with heroin, counterfeit prescription pills (oxycodone-lookalike pills), cocaine and methamphetamine. IMF is 50-100× more potent than morphine — a lethal dose is approximately 2mg (the size of a few grains of salt). Carfentanil (elephant tranquiliser) is 10,000× more potent than morphine.
Opioid use disorder (OUD)
WHO/DSM-5A chronic relapsing brain disorder — characterised by compulsive opioid use despite harm, craving, and physical dependence. DSM-5 criteria: impaired control, social impairment, risky use, pharmacological tolerance and withdrawal. WHO ICD-11 equivalent: opioid dependence. Effective treatment: medications for opioid use disorder (MOUD) — methadone, buprenorphine, naltrexone — combined with psychosocial support.
Naloxone (Narcan)
WHO EMLA competitive opioid receptor antagonist — displaces opioid agonists from mu-opioid receptors within 2-3 minutes, reversing respiratory depression, sedation and unconsciousness from opioid overdose. Available as: nasal spray (Narcan NS 4mg — most widely distributed); IM injection; IV; auto-injector. Duration of action: 30-90 minutes — shorter than many opioids, requiring repeat dosing and monitoring. WHO EML. Community naloxone distribution to people who use drugs and their contacts is a core harm reduction strategy.
Methadone
WHO EMLA long-acting full opioid agonist — reducing opioid cravings and preventing withdrawal without producing euphoria (at stable dosing). Daily supervised dispensing in licensed opioid treatment programmes (OTPs). Reduces illicit opioid use by approximately 50-70%, overdose mortality by approximately 50%, and injection-related HIV/HCV transmission. QTc prolongation monitoring required. WHO EML. Most effective MOUD for high-frequency opioid users.
Buprenorphine/naloxone (Suboxone)
FDA/WHOBuprenorphine: a partial mu-opioid agonist — high binding affinity but partial intrinsic activity (ceiling effect reduces overdose risk). Combined with naloxone (added to deter injection misuse — sublingual naloxone has low bioavailability). Advantages over methadone: prescribable in office-based settings (lower barrier to treatment), lower overdose risk (ceiling effect), take-home doses. Less effective than methadone for severe OUD. On WHO EML (buprenorphine alone).
Purdue Pharma and OxyContin — the origin
US DoJ/SacklerIn 1996, Purdue Pharma launched OxyContin (controlled-release oxycodone) with an aggressive, fraudulent marketing campaign claiming it had low addiction potential — fuelling massive over-prescribing of opioids for chronic non-cancer pain. The resulting prescription opioid epidemic led to 300,000+ overdose deaths in the US 1999-2019. Purdue Pharma pleaded guilty to federal criminal charges in 2020; the Sackler family agreed to a $6B+ settlement. This pharmaceutical-driven public health catastrophe led to the tightest opioid prescribing regulations in US history.

Latest GMJ coverage

Corrected Global Data on Substance Use Burden Across 204 Countries Reveals Shifting Patterns
09/07/2026
Moldova probation centres identify 136 people with opioid disorders through innovative screening programme
29/05/2026
Republican Opposition to Opioid Treatment Medications Sparks Policy Debate
25/06/2026
AI Drug Monitoring System Failed to Detect Months of Fentanyl Theft at Tennessee Hospital
03/06/2026
Largest review finds limited evidence for cannabis in mental health treatment
19/07/2026
How Brain Chemistry Shapes Mood, Sleep, and Focus: A Guide to Neurotransmitters
03/08/2026

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Harm reductionMental health and suicideHIV (PWID transmission)HCV (PWID transmission)Mental health comorbidity

About this hub. Produced by the GMJ News Editorial Team as a public-good service. Every statistic is linked to its primary source. Documents are preserved in the GMJ Repository with full attribution. Georgian Medical Journal · Contact the editorial team
GMJ BriefsView all →
●Understanding the Three-Part Strategy Behind New Periodontal Disease Research3 hours ago●23 Million Patient Records Now Enable Real-World Pregnancy Drug Safety Research3 hours ago●Announcement: How Your Brain’s Wiring Controls Everything: A Guide to the Nervous System3 hours ago●What Patients Should Know: OLE Targets Neuroinflammation in Emerging Alzheimer's Therapy1 hour ago●Announcement: Why Your Spine Is Your Body’s Critical Nerve Highway: Understanding Spinal Function and Health1 hour ago●Nearly Half of Older Adults Defy Decline Trajectory, Yale Data Shows56 minutes ago●Three Evidence-Based Dietary Strategies to Maximize Cardiovascular Protection Through Flavanol-Rich Foods56 minutes ago●Announcement: The Spine as Neural Gateway: How Spinal Health Affects Whole-Body Function56 minutes ago●One Mutation, Multiple Benefits: The Inflammation-Suppressing Variant Reshaping Longevity Research3 hours ago●Announcement: How Gut Dysbiosis Triggers Systemic Inflammation: A Mechanistic Overview3 hours ago